Worth reading
52Recurring
Scored from 3 of 4 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
19.99
% or less (number of common shares and voting rights to be issued before shareholder approval)Wording
Avoiding a definitive answer
How definitive the wording is.Resolutions for the General Meeting of Shareholders
Annual (annual meeting of shareholders)2026
Jun 10
Date and time(local time)54 days from this disclosure to the meeting
Matters for resolution1 item
Proposals concerning the election of directors and the issuance of common shares upon conversion of the Series B Convertible Preferred Stock
| Item | Details |
|---|---|
| Type of shareholders' meeting | Annual (annual meeting of shareholders) |
| Date and time | 10 June 2026 (local time) |
| Matters for resolution | Proposals concerning the election of directors and the issuance of common shares upon conversion of the Series B Convertible Preferred Stock |
Items this document does not state (3)
Shareholder ProposalDirector nomineePercentage voting in favor
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The acquisition structure provides Gyre Therapeutics common shares and Series B Convertible Preferred Stock as consideration for the acquisition of Cullgen shares. Under Nasdaq listing rules, shareholder approval is required for the issuance of more than 20% of the common shares.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.